Overview
| Generic Names: | Desacetylvinblastine Amide Sulfate; Vindesine Sulfate |
|---|---|
| Trade Names: | DAVA; Eldesine; Eldisine |
| PharmGKB Accession Id: | PA10232 |
Description
Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols). [PubChem]
Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
ATC Therapeutic Category
- L01CA:Vinca alkaloids and analogues
Pharmacology and Interactions
Mechanism Of Action
Vindesine acts by causing the arrest of cells in metaphase mitosis through its interaction with tubulin. The drug is cell-cycle specific for the S phase.
Pharmacology
Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic
Protein Binding
65-75%
Half Life
24 hours.
Chemical Properties
Chemical Formula:
C43H55N5O7
SMILES Code:
CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CC[N@@]9[C@H]7[C@@](C=CC9 )([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
(Format: OpenEye Isomeric)
Molecular Weight ( average / monoisotopic )
753.9261 / 753.4101
Curated Information
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ABCB1 |
|
Pathways |
|
|
ABCB11 |
|
Pathways |
|
|
ABCB4 |
|
Pathways |
|
|
ABCC1 |
|
Pathways |
|
|
ABCC10 |
|
Pathways |
|
|
ABCC2 |
|
Pathways |
|
|
CYP3A4 |
|
Pathways |
|
|
CYP3A5 |
|
Pathways |
|
|
RALBP1 |
|
Pathways |
Non-Curated Information
A list of non-curated publications that mention this drug along with other genes is available.
Metabolizing Enzymes
Drug Targets
PharmGKB Curated Pathways
Non-Curated Information
A list of non-curated publications that mention this drug along with other drugs is available.
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Hodgkin Disease |
|
Pathways |
|
|
Lymphoma, Non-Hodgkin |
|
Pathways |
|
|
Multiple Myeloma |
|
Pathways |
|
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Pathways |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
